NEW YORK, April 2, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community.Today we are offering reports on SNN, SYK, VRAY, and ZBH which can be accessed for free by signing up to www.wallstequities.com/registration. WallStEquities.com revisits the Medical Appliances and Equipment space, which is engaged in the manufacturing
Smith & Nephew
Shares in London, the UK headquartered Smith & Nephew PLC saw a slight decline of 0.78%, ending last Thursday's trading session at $38.15. The stock recorded a trading volume of 755,192 shares. The Company's shares have gained 7.56% in the last month, 8.57% over the last three months, and 23.14% over the past year. The stock is trading 4.94% and 6.14% above its 50-day and 200-day moving averages, respectively. Moreover, shares of the Company, which designs, develops, and sells medical devices worldwide, have a Relative Strength Index (RSI) of 60.33.
On March 19th, 2018, Smith & Nephew announced the donation of more than $3M of trauma plates and screws, external fixation implants and instruments to The Podiatry Institute (PI). This equipment will be used to support ongoing educational courses conducted at the PI through the American Academy of Foot and Ankle Osteosynthesis. Get the full research report on SNN for free by clicking below at:
Kalamazoo, Michigan headquartered Stryker Corp.'s stock climbed 1.87%, closing the day at $160.92. A total volume of 1.58 million shares was traded, which was above their three months average volume of 1.32 million shares. The Company's shares have advanced 3.41% in the previous three months and 22.00% over the past year. The stock is trading 6.27% above its 200-day moving average. Additionally, shares of Stryker, which operates as a medical technology company, have an RSI of 45.23.
On March 15th, 2018, research firm Raymond James initiated an 'Outperform' rating on the Company's stock, with a target price of $183 per share.
On March 22nd, 2018, Stryker announced that its final operating results for the quarter ended March 31st, 2018, will be released at 4:05 p.m. on April 26th, 2018. The Company will host a conference call at 4:30 p.m. ET that same day to discuss its results and provide an operational update. A simultaneous webcast of the call will be accessible on the Company's website. Access the free research report on SYK now by signing up at:
On Thursday, shares in Oakwood Village, Ohio headquartered ViewRay Inc. recorded a trading volume of 659,534 shares. The stock ended the day 1.98% lower at $6.43. The Company's shares are trading below their 200-day moving average by 11.41%. Furthermore, shares of ViewRay, which through its subsidiary, ViewRay Technologies, Inc., designs, manufactures, and markets radiation therapy systems, have an RSI of 31.22.
On March 27th, 2018, ViewRay announced that it surpassed its 50 MRIdian MR image-guided radiation therapy system order during the first quarter of 2018 — a landmark achievement in ViewRay's history of bringing next-generation technology to the fight against cancer. MRIdian is the only FDA-cleared and CE-marked MR-image guided radiation therapy system. Are you already registered with Wall St. Equities? Do so now for free, and get the report on VRAY at:
Zimmer Biomet Holdings
Warsaw, Indiana headquartered Zimmer Biomet Holdings Inc.'s stock rose slightly 0.81%, finishing yesterday's session at $109.04. A total volume of 1.36 million shares was traded, which was above their three months average volume of 1.33 million shares. The Company's shares are trading below their 50-day moving average by 8.35%. Additionally, shares of Zimmer Biomet, which together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, EMEA region, and Asia/Pacific, have an RSI of 33.67.
On March 12th, 2018, Zimmer Biomet announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the first quarter of 2018. The cash dividend of $0.24 per share will be paid on or about April 30th, 2018, to stockholders of record as of the close of business on March 29th, 2018.
On March 15th, 2018, research firm Raymond James initiated an 'Outperform' rating on the Company's stock. Aspiring Member, please take a moment to register below for your free research report on ZBH at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: firstname.lastname@example.orgPhone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/technical-perspectives-on-medical-equipment-stocks----smith--nephew-stryker-viewray-and-zimmer-biomet-300622507.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Self-medication is treating self with non-prescription or over the counter medications, for ...
Art of gardening can improve socializing and cognitive skills in children and elderly. As a therapy ...
Prunes are dried plums that are packed with nutrients like vitamins and minerals that are essential ...View All